GP6 and stroke disorder: Targeting this receptor was therefore not believed to lead to unacceptable effects on haemostasis and has warranted further study.23 In keeping with this, in a recently published clinical trial of the GPVI inhibitor glenzocimab in stroke, glenzocimab was not associated with higher rates of intracranial haemorrhage than placebo.24